These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. Goldhaber SZ; Kessler CM; Heit JA; Elliott CG; Friedenberg WR; Heiselman DE; Wilson DB; Parker JA; Bennett D; Feldstein ML J Am Coll Cardiol; 1992 Jul; 20(1):24-30. PubMed ID: 1607532 [TBL] [Abstract][Full Text] [Related]
5. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. Dalla-Volta S; Palla A; Santolicandro A; Giuntini C; Pengo V; Visioli O; Zonzin P; Zanuttini D; Barbaresi F; Agnelli G J Am Coll Cardiol; 1992 Sep; 20(3):520-6. PubMed ID: 1512328 [TBL] [Abstract][Full Text] [Related]
6. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Goldhaber SZ; Kessler CM; Heit J; Markis J; Sharma GV; Dawley D; Nagel JS; Meyerovitz M; Kim D; Vaughan DE Lancet; 1988 Aug; 2(8606):293-8. PubMed ID: 2899718 [TBL] [Abstract][Full Text] [Related]
7. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group. Goldhaber SZ; Agnelli G; Levine MN Chest; 1994 Sep; 106(3):718-24. PubMed ID: 8082347 [TBL] [Abstract][Full Text] [Related]
8. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Verstraete M; Miller GA; Bounameaux H; Charbonnier B; Colle JP; Lecorf G; Marbet GA; Mombaerts P; Olsson CG Circulation; 1988 Feb; 77(2):353-60. PubMed ID: 3123091 [TBL] [Abstract][Full Text] [Related]
9. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Levine M; Hirsh J; Weitz J; Cruickshank M; Neemeh J; Turpie AG; Gent M Chest; 1990 Dec; 98(6):1473-9. PubMed ID: 2123152 [TBL] [Abstract][Full Text] [Related]
10. Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators. Chest; 1990 Mar; 97(3):528-33. PubMed ID: 2106408 [TBL] [Abstract][Full Text] [Related]
11. Recombinant tissue plasminogen activator in patients with pulmonary embolism: correlation of fibrinolytic specificity and efficacy. Vaughan DE; Goldhaber SZ; Kim J; Loscalzo J Circulation; 1987 Jun; 75(6):1200-3. PubMed ID: 3105914 [TBL] [Abstract][Full Text] [Related]
12. Extended infusion of rtPA lysis of pulmonary emboli: influence of time after onset of symptoms on outcome. Aschauer M; Pilger E; Szolar DH; Flueckiger F; Hausegger K; Stark G; Groell R; Klein GE; Schreyer H Cardiovasc Intervent Radiol; 1995; 18(5):288-90. PubMed ID: 8846466 [TBL] [Abstract][Full Text] [Related]
13. Early reversal of right ventricular dysfunction in patients with acute pulmonary embolism after treatment with intravenous tissue plasminogen activator. Come PC; Kim D; Parker JA; Goldhaber SZ; Braunwald E; Markis JE J Am Coll Cardiol; 1987 Nov; 10(5):971-8. PubMed ID: 2959713 [TBL] [Abstract][Full Text] [Related]
14. [The thrombolytic treatment of acute and subacute recurrent pulmonary embolism with recombinant tissue plasminogen activator]. Tiede N; Kasper W; Geibel A; Bassenge D; Langenstein B; Meinertz T; Just H Dtsch Med Wochenschr; 1990 Nov; 115(45):1699-704. PubMed ID: 2121453 [TBL] [Abstract][Full Text] [Related]
15. [Thrombolysis in resuscitated patients with pulmonary embolism]. Scholz KH; Hilmer T; Schuster S; Wojcik J; Kreuzer H; Tebbe U Dtsch Med Wochenschr; 1990 Jun; 115(24):930-5. PubMed ID: 2113453 [TBL] [Abstract][Full Text] [Related]
16. Successful treatment of massive pulmonary embolism with recombinant tissue type plasminogen activator (rt-PA) in a pregnant woman with intact gravidity and preterm labour. Flossdorf T; Breulmann M; Hopf HB Intensive Care Med; 1990; 16(7):454-6. PubMed ID: 2125304 [TBL] [Abstract][Full Text] [Related]
17. A new short infusion dosage regimen of recombinant tissue plasminogen activator in patients with venous thromboembolic disease. Levine MN; Weitz J; Turpie AG; Andrew M; Cruickshank M; Hirsh J Chest; 1990 Apr; 97(4 Suppl):168S-171S. PubMed ID: 2108854 [TBL] [Abstract][Full Text] [Related]
18. [A case of successful application of tissue plasminogen activator actilyse in complex intensive therapy for massive pulmonary artery embolism]. Mierbekov EM; Artykbaev ZhT; Potseluev DD Anesteziol Reanimatol; 2004; (2):67-70. PubMed ID: 15206285 [No Abstract] [Full Text] [Related]
19. Incidence and predictors of major hemorrhagic complications from thrombolytic therapy in patients with massive pulmonary embolism. Meyer G; Gisselbrecht M; Diehl JL; Journois D; Sors H Am J Med; 1998 Dec; 105(6):472-7. PubMed ID: 9870831 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Wang C; Zhai Z; Yang Y; Wu Q; Cheng Z; Liang L; Dai H; Huang K; Lu W; Zhang Z; Cheng X; Shen YH; Chest; 2010 Feb; 137(2):254-62. PubMed ID: 19741062 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]